Subcutaneous · GIP agonist
LY3537021
3 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
3
Ongoing
1
Recruiting
1
Completed
2
Sites
68
Countries
11
Endpoints
9
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Phase 2
1
Trials by status
Recruiting
1
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
7
Other (unclassified)
2
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
3 of 3
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07169851A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | LY3537021 Oncology | - | Ph 2 | Recruiting | 67 | Dec 2026 | - | |
| NCT05444569A Study of LY3537021 in Healthy Participants | Liraglutide, LY3537021 Healthy volunteers | BMI 23-40 | Ph 1 | Completed | 1 | Feb 2023 | - | |
| NCT04586907A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | LY3537021 Healthy volunteers, Type 2 diabetes | BMI 18.5-40 | Ph 1 | Completed | 1 | Nov 2021 | 1 |
Showing 1-3 of 3 trials